Featured news | Nanologica

Nanologica Delivers Silica to Insulin Manufacturer

17 October, 2023

Nanologica delivers silica to an insulin manufacturer in Asia against an order received last year. The delivery consists of silica for evaluation in full-scale production. The delivery is made against an order that was placed last year and Nanologica will provide the silica free of charge in return for being provided with results and insights into the final evaluation. The customer, which is one of the world’s largest insulin manufacturers, finances all other costs for

CEO Andreas Bhagwani is interviewed at Redeye after the release of the interim report Q2 2023

8 July, 2023

Intervju med vd Andreas Bhagwani gällande delårsrapporten för Q2 2023.

Interim Report Q2 2023 Nanologica AB (publ)

7 July, 2023

FINANCIAL SUMMARY Net sales for the second quarter amounted to TSEK 672 (210) and for the half-year to TSEK 1,026 (479) The operating loss for the quarter amounted to TSEK -13,312 (-12,397) and for the half-year to TSEK -24,032 (-27,989) Loss after tax for the quarter amounted to TSEK -14,671 (-13,473) and for the half-year to TSEK -26,764 (-29,388) Earnings per share before and after dilution were SEK -0.41 (-0.48) for the quarter and SEK

Nanologica söker en Business Controller

29 June, 2023

Är du driven och motiveras av varierande arbetsuppgifter? Har du erfarenhet från producerande noterat bolag? Lockas du av en expansiv innovativ verksamhet? Då kan du vara den Business Controller som Nanologica söker! Vad får dig att trivas hos uppdragsgivaren Hos Nanologica får du jobba på ett bolag som vill förbättra för mänskligheten genom att bidra till att öka tillgängligheten till insulin och andra livsnödvändiga mediciner för patienter världen över. Bolaget är i början av en

Nanologica Delivers Silica to Latin-American Customer for Production of Insulin

1 June, 2023

As a result of Nanologica’s product in preparative chromatography, NLAB Saga®, reaching internal quality requirements, silica is now delivered to a customer in Latin America for production of diabetes drugs. The customer is a latin-american pharmaceutical manufacturer that manufactures, among other things, insulin and insulin analogues. This delivery refers to silica for the production of insulin. The delivery is made against a recent order with an order value of about TSEK 300. ”We have for

Redeye Growth Day June 1st

16 May, 2023

Nanologica will participate at Redeye Growth Day 2023 on June 1st. CEO Andreas Bhagwani will present at 11.35. The In Focus interview is live broadcasted at https://www.redeye.se/events/871323/redeye-growth-day

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.